Get the content you want anytime you want.
The Best Infectious Disease News Delivered Weekly

The Contagion® Antibiotics specialty page provides antibiotics-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.


How Can Health Care Practitioners Actively Fight Antibiotic Resistance?
Daniel Pilch, PhD, explains how the health care system must change in order to battle antibiotic resistance.
Early Diagnosis of Multidrug-Resistant Pneumonia Benefits Patient Outcomes
Alan Gross, PharmD, shares how an early diagnosis of multidrug-resistant pneumonia can work towards improving patient outcomes.
Should You Incorporate Penicillin Skin Testing in Your Hospital?
Meghan Jeffres, PharmD, shares what should be considered when considering the incorporation of penicillin skin testing into a health care facility.
Forestalling the Development of Antibiotic Resistance
Edmond LaVoie, PhD, shares different approaches that can be used to forestall the development of antibiotic resistance.
Lyme Disease and Long-Term Antibiotics: Help or Harm?
Panelists Samuel Shor, MD, FACP; Leonard Sigal, MD; Peter L. Salgo, MD; Patricia V. Smith; and Robert C. Bransfield, MD, DLFAPA, debate the existence of chronic Lyme disease and the use of longer-term antibiotics, and explore the impact a lack of consensus has on patients, providers, and the health care system.
How is SIDP Working to Improve Antibiotic Stewardship Programs in LTC Facilities?
Alan Gross, PharmD, BCPS-AQID, shares how the Society of Infectious Diseases Pharmacists is working to improve antibiotic stewardship programs in long-term care facilities.
Ceftolozane-tazobactam: An Alternative Therapy to Treat <i>Pseudomonas</i> Infections
Jason Pogue, PharmD, BCPS-ID, explains the clinical significance of his research team’s findings regarding the use of ceftolozane-tazobactam to treat Pseudomonas infections.
Using Synergistic Combination Drug Therapy to Battle Antibiotic Resistance
Edmond LaVoie, PhD, explains how his team’s approach can be applied in the development of novel drugs for the treatment of drug-resistant infections caused by Gram-negative and Gram-positive bacteria.